Skip to main content
TipRanks
Go Ultimate75% OFF

Arbutus Biopharma (ABUS) Drug Pipeline

1,289 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Ab-101, Nucleos(T)Ide AnalogueChronic Hepatitis BPhase IActive Not RecruitingSafety, Tolerability, PK & PD of AB-101 Following Oral Administration in Healthy and CHB Subjects.Jul 14, 2023―
Ab-729, Peg-Ifnα-2AChronic Hepatitis BPhase IICompletedOpen-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionJul 19, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Arbutus Biopharma (ABUS) have in its pipeline
Arbutus Biopharma ABUS is currently developing the following drugs: Ab-101, Nucleos(T)Ide Analogue, Ab-729, Peg-Ifnα-2A. These drug candidates are in various stages of clinical development as the company works toward FDA approval.